Generalized Myasthenia Gravis Clinical Trials

91 clinical trials for Generalized Myasthenia Gravis across international registries, including 35 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis — RECRUITING · PHASE3
• A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis. — RECRUITING · PHASE2
• RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis — RECRUITING · PHASE1
• Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia — RECRUITING
• Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad) — RECRUITING · PHASE3
• An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis — RECRUITING · PHASE3
• A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis — RECRUITING · PHASE2
• ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod — RECRUITING · PHASE2
• ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis — RECRUITING
• Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis — RECRUITING · PHASE3
• A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis — RECRUITING · PHASE3
• KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis — RECRUITING · PHASE2
• A Phase 2 Open-label Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children From 2 Years to less than 18 Years of age With Generalized Myasthenia Gravis (gMG) — RECRUITING · PHASE2
• A Long-term, Single-Arm, Open-label, Multicenter Trial to Evaluate Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis — RECRUITING · PHASE3
• A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG) — RECRUITING · PHASE2
• Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis — RECRUITING · PHASE1
• A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) — RECRUITING · PHASE3
• Monitor the Evolution of Myasthenia Gravis Symptoms in Real-life in Patients With Anti-AChR and Anti-MUSK Generalised Myasthenia Gravis in Therapy With RYSTIGGO® (Rozanolixizumab) — RECRUITING
• A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis — RECRUITING · PHASE2
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study with an Open-label Extension Period to Evaluate the Efficacy and Safety of Telitacicept in Patients with Generalized Myasthenia Gravis — RECRUITING · PHASE3
• A Study to Evaluate the Impact of Efgartigimod on Overall Disease Experience of People Suffering From Generalized Myasthenia Gravis (gMG) in Italy — RECRUITING
• Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis — RECRUITING · PHASE2
• A PHASE 2, RANDOMIZED, BLINDED, PLACEBOCONTROLLED, STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOMETRICS, AND EFFICACY OF DNTH103 IN ADULTS WITH GENERALIZED MYASTHENIA GRAVIS (MAGIC) — RECRUITING · PHASE2
• Study of Ultomiris® (Ravulizumab) Safety in Pregnancy — RECRUITING
• A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab — RECRUITING · PHASE4
• PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis — RECRUITING · PHASE3
• Zilucoplan for Severe gMG Exacerbations — RECRUITING · PHASE3
• Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs) — RECRUITING
• Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis — RECRUITING · PHASE2
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, 3-Period Study to Assess the Efficacy and Safety of a New Formulation of Oral Cladribine Compared with Placebo in Participants with Generalized Myasthenia Gravis (MyClad) — RECRUITING · PHASE3
• Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis — RECRUITING
• Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG) — RECRUITING · PHASE1
• GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103) — RECRUITING · PHASE1
• Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Myasthenia Gravis — RECRUITING · NA
• Seronegative Myasthenia Gravis - Efgartigimod IV — RECRUITING · PHASE3
• STUDY OF ECULIZUMAB IN REFRACTORY GENERALIZED MYASTHENIA GRAVIS (GMG)SUBJECTS — COMPLETED · PHASE3
• A Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Multi-Center Study of Eculizumab in Patients with Generalized Myasthenia Gravis (gMG) Who Have Moderate to Severe Muscle Weakness Despite Treatment with Immunosuppressants. — TERMINATED · PHASE2
• A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis — ACTIVE_NOT_RECRUITING · PHASE2
• A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG. — ACTIVE_NOT_RECRUITING · PHASE3
• Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis — COMPLETED · PHASE3
• Efficacy and Safety of HN2301 in Patients With Generalized Myasthenia Gravis (MG) — NOT_YET_RECRUITING · PHASE1
• A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis — ACTIVE_NOT_RECRUITING · PHASE3
• A Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of Aritinercept, a Dual BAFF/APRIL Inhibitor, in Patients with Generalized Myasthenia Gravis — TERMINATED · PHASE2
• ARGX-113-2207: An Open-label, Uncontrolled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Efgartigimod PH20 SC in Participants From 2 to Less Than 18 Years of Age With Generalized Myasthenia Gravis — TERMINATED · PHASE3
• Universal STAR-T Cell Injection in Generalized Myasthenia Gravis — NOT_YET_RECRUITING · PHASE1
• A Phase 2/3, Open-Label, Randomized, Controlled, Multicenter Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, Versus Ongoing Standard-Of-Care Immunosuppressive Therapy in Patients with Generalized Myasthenia Gravis (KYSA-6) — TERMINATED · PHASE3
• A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis — ACTIVE_NOT_RECRUITING · PHASE3
• A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of IMVT-1402 in Patients With Mild to Severe Generalized Myasthenia Gravis — TERMINATED · PHASE3
• A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of remibrutinib in patients with generalized myasthenia gravis, followed by an open-label extension phase. — TERMINATED · PHASE3
• Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG) — NOT_YET_RECRUITING · PHASE3

Refine this search